Iteos Home

Press Releases

Home / Investors / iTeos Therapeutics to Present at Upcoming March Conferences

Press Release Details

iTeos Therapeutics to Present at Upcoming March Conferences

March 5, 2018
PDF Version

Gosselies, Belgium – March 5, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that Michel Detheux, Ph.D., Chief Executive Officer of iTeos will present at two upcoming March conferences as follows:

 

  • Cowen 38th Annual Health Care Conference on Monday, March 12, 2018 at 1:00 p.m. ET in Boston, MA.
  • Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018 at 2:45 p.m. ET in New York, NY. 

 

Additionally, Mohamed Ragab, M.D, Vice President of Corporate Development of iTeos, will be available for one-on-one meetings at BIO-EUROPE SPRING, the 12th Annual International Partnering Conference, on Monday, March 12, 2018 in Amsterdam, The Netherlands.

 

About iTeos Therapeutics

Starting operations in 2012, iTeos Therapeutics is a clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by developing immunotherapies by design.  iTeos is developing EOS200271, a clinical-stage potent and selective IDO1 inhibitor with exceptional brain penetration. The company is also advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase 1 trial in the second half of 2018; and a human ADCC-enabling anti-TIGIT antibody (EOS884448), representing an additional, third clinical entry in 2019. Based in Gosselies, Belgium, iTeos Therapeutics was founded and supported in part by investments from the Ludwig Institute Cancer Research (LICR), the Walloon Region of Belgium and the European Fund for Economic and Regional Development (FEDER). For more information, please visit www.iteostherapeutics.com.

 

For further information, please contact:

Michel Detheux, CEO
iTeos Therapeutics
info@iteostherapeutics.com 

 

Sarah McCabe and Carl Mauch
Stern Investor Relations, Inc.
+ 1 212 362 1200
iTeos@sternir.com

 

Amber Fennell, Mathew Neal, Hendrik Thys, Suki Virji
Consilium Strategic Communications
+44 203 709 5700
iteos@consilium-comms.com

For investors

scientist picking up a petri dish

At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.

Our differentiated development approach is driven by biologic rationale and clinical need utilizing our IO candidates in intra-portfolio combinations and with programs of external collaborators.

Driven by a culture of scientific innovation, collaboration and excellence, together we discover and deliver breakthrough immunotherapies to improve and extend the lives of people with cancer.